Lisata Therapeutics (LSTA) News
NASDAQ: LSTAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.8989-0.0111 (-1.22%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LSTA news summary
We found 4 recent headlines mentioning Lisata Therapeutics (LSTA): 1 in the past week and 3 in the past 30 days, most often from GlobeNewswire. For price context, LSTA is down 1.22% at $0.8989. The most recent story, "Lisata Therapeutics, Inc. Announces Reverse Stock Split Effective November 23, 2026", was published by GlobeNewswire on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Lisata Therapeutics headlines
- Lisata Therapeutics, Inc. Announces Reverse Stock Split Effective November 23, 2026LIBERTY CORNER, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ: LSTA) (“Lisata” or the “Company”) today announced a one-for-fifteen reverse stock split of its common stock.…GlobeNewswire
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of MedicinePart A of TYDAL-TIMI 78 Trial met all objectives, with statistically significant placebo-adjusted triglyceride reductions of 39.1%–45.5% across all three doses at Week 12 and up to 57.2% in…GlobeNewswire
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor ConferencesSOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a…GlobeNewswire
- Lisata Therapeutics Appoints Jeff Farrow to Board of DirectorsVeteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee Veteran biopharma CFO brings more than…GlobeNewswire